PROBLEM TO BE SOLVED: To provide a pharmaceutical composition which is suitable for treating: a patient with type I and type II diabetes mellitus, prediabetes or reduced glucose tolerance, and further with rheumatoid arthritis, obesity, or calcitonin-induced osteoporosis as well as a patient for which an allograft transplantation has been carried out.SOLUTION: Polymorphic crystal modifications of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)xanthine, their production and their use method for the preparation of a drug are provided.COPYRIGHT: (C)2013,JPO&INPIT【課題】I型及びII型糖尿病、前糖尿病又は減少した糖耐性、さらに関節リウマチ、肥満、又はカルシトニン誘導骨粗鬆症を有する患者、並びに同種移植が行われた患者を治療するのに好適な医薬組成物を提供すること。【解決手段】1-[(4-メチル-キナゾリン-2-イル)メチル]-3-メチル-7-(2-ブチン-1-イル)-8-(3-(R)-アミノ-ピペリジン-1-イル)-キサンチンの多形体結晶修飾、それらの製造及び薬剤の調製のためのそれらの使用方法を提供する。【選択図】なし
